Literature DB >> 1832417

Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro.

K Vogt1, A C Rodloff, H Hahn.   

Abstract

The combined activities of trospectomycin, a spectinomycin analogue, and colloidal bismuth subcitrate against Helicobacter pylori were investigated, the agar dilution method being employed. Forty-seven strains of H. pylori were examined. An additive effect was observed in 89%, and a synergistic interaction in 11% of the isolates. There was no antagonism observed. The MIC50 of trospectomycin against H. pylori was 2 mg/l; the MIC ranged from 0.5 to 4 mg/l.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832417     DOI: 10.1007/bf01643232

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Synergism between clindamycin and colloidal bismuth subcitrate against Helicobacter (Campylobacter) pylori in vitro.

Authors:  K Vogt; H Hahn
Journal:  Zentralbl Bakteriol       Date:  1990-11

2.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species.

Authors:  N V Jacobus; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

4.  In vitro antibacterial activity of trospectomycin (U-63366F), a novel spectinomycin analog.

Authors:  G E Zurenko; B H Yagi; J J Vavra; B B Wentworth
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

5.  Cytopathic effects of Campylobacter pylori urease.

Authors:  M R Barer; T S Elliott; D Berkeley; J E Thomas; E J Eastham
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

Review 6.  Campylobacter pyloridis, gastritis, and peptic ulceration.

Authors:  C S Goodwin; J A Armstrong; B J Marshall
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

7.  Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.

Authors:  C S Goodwin; B J Marshall; E D Blincow; D H Wilson; S Blackbourn; M Phillips
Journal:  J Clin Pathol       Date:  1988-02       Impact factor: 3.411

8.  The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

Authors:  C S Goodwin; P Blake; E Blincow
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

Review 9.  Campylobacter pylori--therapy review.

Authors:  A T Axon
Journal:  Scand J Gastroenterol Suppl       Date:  1989

10.  Antibacterial activity of trospectomycin (U-63366F) and initial evaluations of disk diffusion susceptibility tests.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

View more
  3 in total

1.  Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.

Authors:  Y J Debets-Ossenkopp; F Namavar; D M MacLaren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

2.  In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.

Authors:  T Alarcón; D Domingo; I Sánchez; F Díaz de Rojas; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

3.  In vitro susceptibility of Helicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A).

Authors:  T U Westblom; B R Midkiff; S J Czinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.